France Stem Cell/Cord Blood Banking Market Market Report 2023 to 2030

France Stem Cell/Cord Blood Banking Market Analysis

$ 3999

France Stem Cell/Cord Blood Banking Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Stem Cell/ Cord Blood Banking is expanding as a result of increase in healthcare and growing awareness among people. This demand is fueling the development of market for Stem Cell/Cord Blood Banking. Some of the key players in the global Stem Cell/Cord Blood Banking Market include CBR Systems, Inc., Cordlife, Cryo-Cell International, Inc., ViaCord, Cryo-Save, LifeCell International Pvt. Ltd., StemCyte India Therapeutics Pvt. Ltd., Global Cord Blood Corporation, Smart Cells International Limited, and Vita 34 International.

ID: IN10FRHS101 CATEGORY: Healthcare Services GEOGRAPHY: France AUTHOR: Dr. Nensi Savani

Buy Now

France Stem Cell/Cord Blood Banking Market Executive Summary

France Stem Cell/Cord Blood Banking Market is valued at around $203.5 Bn in 2022 and is projected to reach $360.2 Bn by 2030, exhibiting a CAGR of 7.4% during the forecast period 2023-2030.

Cancer causes 1 in 6 deaths globally, making it one of the major causes of death worldwide. According to World Health Organization, cancer led to 10 Mn deaths in 2020. Cancers including leukemia and multiple myeloma can be successfully treated with stem cell transplantation. The blood-forming stem cells that chemotherapy damaged can be repaired utilizing stem cells. Stem Cell/ Cord Blood Banking is therefore widely employed in research institutions and hospitals as a result of the rising number of cancer patients, and it is also expected to increase dramatically.

A growing trend in the market for Stem Cell/ Cord Blood Banking is the pairing of genetic testing services with the storage of cord blood and tissue. Due to its complementary services, this pairing is possible and effective, helping to increase the product portfolio. This will therefore stimulate market expansion.

Firms CBR Systems, Inc., Cordlife, Cryo-Cell International, Inc., ViaCord, Cryo-Save, LifeCell International Pvt. Ltd., StemCyte India Therapeutics Pvt. Ltd., Global Cord Blood Corporation, Smart Cells International Limited, and Vita 34 International, are some of the major players in the Stem Cell/ Cord Blood Banking Market.

The market for Stem Cells/ Cord Blood Banking services has grown as a result of rising autoimmune disease prevalence and the condition's numerous variants. The primary factor influencing market expansion is the existence of Treg cells in umbilical cords, which are crucial for regulating excessive immune system reactions. With stem cells from cord blood, more than 80 genetic disorders, such as cancer and diabetes, can be cured. The growth of the cord blood banking services sector has been fueled in recent years by the rising incidence of illnesses like Lymphoma, Leukaemia, and Edwards syndrome as well as the immune system and bone marrow disorders like arthritis and Wiskott-Aldrich syndrome.

Some medical organizations have pushed government representatives to push for the adoption of Stem Cell/ Cord Blood Banking services. It is projected that these factors would have a significant impact on the sector growth of Stem Cells/ Cord Blood Banking services. Additionally, the business of providing cord blood banking services has a tremendous amount of potential for growth due to the development of medical treatments, technology, healthcare infrastructure, and R&D. The increasing investments in the industry are expected to hasten this expansion.

Market Dynamics

Drivers of France Stem Cell/Cord Blood Banking Market

Increasing Prevalence of Hematological Disorders: Blood and blood-forming organs are related to hematological disease. The prevalence of these disorders is constantly increasing and includes thalassemia, sickle cell anemia, leukemia, lymphoma, hemophilia, and others. The need for Stem Cells/ Cord Blood is rising as a result of the exponentially increasing prevalence of leukemia patients around the world.

Increase in Healthcare Infrastructure: The value of Stem Cells/ Blood Cells Banking is expected to grow as a storage infrastructure for cord blood is developed in both public and private healthcare settings.

Growing Awareness Among People: As more people become aware of the benefits of Stem Cells/ Cord Blood, there will be a greater need for hospitals to process cord blood, which will drive market growth.

Developments in Stem Cell/Cord Blood Banking Market

In 2023, For the treatment of a rare blood condition, the FDA approved the first medication generated from cord blood. As it paves the path for the discovery and commercialization of more stem cell-based medicines, this approval represents a significant turning point for the stem cell/cord blood banking sector.

In 2022, Cryo-Cell International, Inc. reported that it has entered into a purchase contract for a recently constructed, 56,000 sq ft facility located in the Regional Commerce Center within the Research Triangle, NC, with the closure subject to customary conditions. This facility is expected to grow Cryo-cryopreservation Cells and cold storage business by launching a new service, ExtraVault.

In September 2022, three distinct dose levels of the stem cell product XSTEM will be tested in Australia as part of Xintela's first-in-human trial (Phase I/IIa) for the treatment of knee osteoarthritis. The lowest dose level has now been administered to all patients. Xintela created and produces XSTEM, which is made up of allogeneic (donated) mesenchymal stem cells that have been integrin 101-selected. An injection of XSTEM is given to patients with moderate knee osteoarthritis (grade II–III). Up to 54 individuals at three different dose levels will be studied, and each patient will have an 18-month follow-up with a 6-month efficacy readout. The main objective is to demonstrate the safety of XSTEM while also examining early efficacy indicators such as decreased joint cartilage degradation, regrowth of damaged cartilage, and enhanced joint function.

Key players

Institut de Recherche en Bioth?rapie (IRB) StemCryo Cordialis EFS (French Blood Establishment) Hemobioscience Amniotic France AlphaCord Cryo-Save France Magelis Biotechnologies Biolokal

1. Executive Summary
1.1 Service Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Healthcare Services Market in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Services
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Market Segmentations For France Stem Cell/Cord Blood Banking Market

By Storage Type

Private Banks
Public Banks
Hybrid Banks

By Product Type

Cord Blood
Cord Tissue

By Service Type

Collection & Transportation
Processing
Analysis
Storage

By Source

Umbilical Cord Blood
Bone Marrow
Peripheral Blood Stem
Menstrual Blood

By Indication

Cerebral Palsy
Thalassemia
Leukemia
Diabetes
Autism

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.